KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Receivables (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Receivables for 15 consecutive years, with $189.6 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 29.8% to $189.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189.6 million through Dec 2025, up 29.8% year-over-year, with the annual reading at $189.6 million for FY2025, 29.8% up from the prior year.
  • Receivables for Q4 2025 was $189.6 million at Supernus Pharmaceuticals, up from $177.6 million in the prior quarter.
  • The five-year high for Receivables was $189.6 million in Q4 2025, with the low at $127.1 million in Q1 2021.
  • Average Receivables over 5 years is $149.8 million, with a median of $145.9 million recorded in 2024.
  • The sharpest move saw Receivables fell 13.61% in 2023, then increased 29.8% in 2025.
  • Over 5 years, Receivables stood at $148.9 million in 2021, then rose by 11.12% to $165.5 million in 2022, then fell by 12.9% to $144.2 million in 2023, then increased by 1.33% to $146.1 million in 2024, then rose by 29.8% to $189.6 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $189.6 million, $177.6 million, and $146.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.